<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078193</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-302</org_study_id>
    <nct_id>NCT02078193</nct_id>
  </id_info>
  <brief_title>Efficacy of Belatacept in Reducing DSA</brief_title>
  <official_title>An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific Human Leukocyte Antigen (HLA) Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that administration of belatacept in
      maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody
      (DSA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate patients converted to belatacept in combination with
      Mycophenolate Mofetil (MMF) with corticosteroids with respect to their DSA titer. Patients in
      this study will be converted from their calcineurin inhibitor (CNI) to belatacept from
      baseline in an attempt to down-modulate antibody production by B-cells. Dosing will be
      calculated per prescribing information for dosing maintenance phase (5mg per kg every 28
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Donor Specific Antibodies (DSA)</measure>
    <time_frame>one year</time_frame>
    <description>DSA levels will be measured using microbeads coated with Class I or Class II human leukocyte antigens (HLA) and read using a Luminex flow cytometer. Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>one year</time_frame>
    <description>Incidence of infections</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Chronic Kidney Rejection</measure>
    <time_frame>One year</time_frame>
    <description>Incidence of chronic kidney rejection</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be converted from their current MMF to once a month infusions of Belatacept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Patients will be converted from their MMF to Belatacept</description>
    <arm_group_label>Belatacept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of cadaveric, living related or living unrelated kidney transplant with
             positive DSA titer (two positive tests) and enrolled within 6 months of DSA detection.

          -  Patients with stable renal function. Stable renal function is defined as one serum
             creatinine (SCr) value that is +/- 10% of the baseline SCr within 3 months of
             enrollment (eGFR &gt;/= 35 and &lt;/= 75 mL/min/1.73m^2).

          -  Patients who are EBV seropositive

          -  Males and females, 18-75 years of age;

          -  Patients currently receiving mycophenolic acid (MPA) (CellCept daily or myfortic
             daily), cyclosporine or tacrolimus with corticosteroids as part of their
             immunosuppressive regimen

          -  Patients willing to be converted to belatacept from cyclosporine or tacrolimus.

          -  Females of childbearing potential must have a negative pregnancy test prior to
             enrollment. The test should be performed at baseline visit. Effective contraception
             must be used during the trial, and for 4 weeks following discontinuation of the study
             medication;

          -  Patients who are willing and able to participate in the full course of the study and
             from whom written informed consent has been obtained.

        Exclusion Criteria:

          -  Multi-solid or cellular organ transplants (e.g. combined with pancreas, liver, islet,
             bone marrow), either concurrent or previous (with exception that a second kidney
             transplant is allowed);

          -  Evidence of graft rejection or treatment of acute rejection within 14 days prior to
             Baseline visit;

          -  Patients who have received any investigational drug within 4 weeks prior to study
             entry;

          -  Patients with HLA identical

          -  Patients who are Epstein-Barr virus (EBV) seronegative

          -  Presence of clinically significant infection requiring continued therapy, chronic
             infection (e.g. HIV, Hep B and Hep C), malignancy (within last 5 years, except excised
             squamous or basal cell carcinoma of the skin), lymphoma or renal toxicity that would
             interfere with the appropriate conduct of the study;

          -  Evidence of severe liver disease (incl. abnormal liver profile i.e. Aspartate
             Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin &gt;/= 3 times
             ULN) or severe diarrhea or active peptic ulcer disease that would interfere with the
             appropriate conduct of the study;

          -  Abnormal physical or laboratory findings of clinical significance within 2 weeks of
             inclusion which would interfere with the objectives of the study;

          -  Patients with symptoms of significant somatic or mental illness or evidence of drug
             and/or alcohol abuse;

          -  Patients receiving &gt; 10 mg/day prednisone dose;

          -  History of hypersensitivity to any of the study drugs or to drugs with similar
             chemical structures to belatacept;

          -  Patients not making DSA antibodies;

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test (local); females of
             childbearing potential who are unwilling to use effective study-approved
             contraceptives and who are planning to become pregnant; Sexually active fertile men
             must use effective birth control if their partners are women of child bearing
             potential;

          -  Any other medical condition that, in the opinion of the site investigator based on
             recall or chart review would interfere with completing the study, including but not
             limited to visual problems or cognitive impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University, Department Chair of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <results_first_submitted>May 16, 2017</results_first_submitted>
  <results_first_submitted_qc>June 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Carolina University</investigator_affiliation>
    <investigator_full_name>Paul Bolin</investigator_full_name>
    <investigator_title>Dr. Paul Bolin, MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belatacept</title>
          <description>All patients enrolled will be converted to Belatacept from prograf.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belatacept</title>
          <description>All patients enrolled will be converted to Belatacept from prograf.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Donor Specific Antibodies (DSA)</title>
        <description>DSA levels will be measured using microbeads coated with Class I or Class II human leukocyte antigens (HLA) and read using a Luminex flow cytometer. Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept</title>
            <description>Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept
Belatacept: Patients will be converted from their MMF to Belatacept</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Donor Specific Antibodies (DSA)</title>
          <description>DSA levels will be measured using microbeads coated with Class I or Class II human leukocyte antigens (HLA) and read using a Luminex flow cytometer. Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept.</description>
          <units>percent change in DSAs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Incidence of infections</description>
        <time_frame>one year</time_frame>
        <population>Number of participants with infections</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept</title>
            <description>Participants who received Belatacept by IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Incidence of infections</description>
          <population>Number of participants with infections</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Chronic Kidney Rejection</title>
        <description>Incidence of chronic kidney rejection</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept</title>
            <description>Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept
Belatacept: Patients will be converted from their MMF to Belatacept</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Kidney Rejection</title>
          <description>Incidence of chronic kidney rejection</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Belatacept</title>
          <description>All patients enrolled will be converted to Belatacept from prograf.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Austin Rice</name_or_title>
      <organization>East Carolina University, Division of Nephrology</organization>
      <phone>252-744-1904</phone>
      <email>riceau15@ecu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

